Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1239 Results

Title
Intervention Indication Therapeutic Area Year Actions
Pegzilarginase for Arginase-1 deficiency Pegzilarginase (AEB1102; Loargys) Hyperargininemia Endocrine Nutritional and Metabolic Disorders 2021 View  |  Download
Pembrolizumab (Keytruda) for advanced gastric or gastroesophageal junction adenocarcinoma – first line Pembrolizumab (Keytruda; MK-3475) Gastric cancer , Gastro-oesophageal junction cancer Gastrointestinal Cancer 2017 View  |  Download
Pembrolizumab (KEYTRUDA) for advanced, metastatic oesophageal cancer – second line Pembrolizumab (Keytruda; MK-3475) Gastro-oesophageal junction cancer , Oesophageal cancer Gastrointestinal Cancer , Head and Neck Cancer 2017 View  |  Download
Pembrolizumab (Keytruda) for metastatic castration‐resistant prostate Pembrolizumab (Keytruda; MK-3475) Prostate cancer Male Reproductive Cancer 2017 View  |  Download
Pembrolizumab (Keytruda) for non‐small cell lung cancer - first line, previously untreated Pembrolizumab (Keytruda; MK-3475) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2017 View  |  Download
Pembrolizumab (Keytruda) for relapsed/refractory classical Hodgkin lymphoma Pembrolizumab (Keytruda; MK-3475) Hodgkin lymphoma Haematological Cancer and Lymphomas 2018 View  |  Download
Pembrolizumab (Keytruda) for triple negative breast cancer Pembrolizumab (Keytruda; MK-3475) Breast cancer Breast Cancer 2017 View  |  Download
Pembrolizumab (KEYTRUDA) in combination with carboplatin-paclitaxel/Nab-paclitaxel for metastatic squamous non small cell lung cancer, first line Carboplatin (Paraplatin) , Nab-Paclitaxel (Abraxane; ABI 007; ABI-007) , Paclitaxel (Taxol; paclitaxel albumin) , Pembrolizumab (Keytruda; MK-3475) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2017 View  |  Download
Pembrolizumab addition to chemotherapy, followed by maintenance with olaparib for BRCA non-mutated advanced epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer – First-line Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) , Pembrolizumab (Keytruda; MK-3475) Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer Female Reproductive Cancer 2020 View  |  Download
Pembrolizumab adjuvant for urothelial carcinoma and/or localised muscle invasive bladder cancer Pembrolizumab (Keytruda; MK-3475) Urothelial cancer Urological Cancer 2024 View  |  Download
1 2 79 80 81 82 83 123 124
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications